Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.